✦ LIBER ✦

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

✍ Scribed by Francisco M Marty; Per Ljungman; Genovefa A Papanicolaou; Drew J Winston; Roy F Chemaly; Lynne Strasfeld; Jo-Anne H Young; Tulio Rodriguez; Johan Maertens; Michael Schmitt; Hermann Einsele; Augustin Ferrant; Jeffrey H Lipton; Stephen A Villano; Hongzi Chen; Michael Boeckh

Book ID: 117791734
Publisher: The Lancet
Year: 2011
Tongue: English
Weight: 259 KB
Volume: 11
Category: Article
ISSN: 1473-3099
DOI: 10.1016/s1473-3099(11)70024-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A novel therapeutic cytomegalovirus DNA

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial

✍ Mohamed A Kharfan-Dabaja; Michael Boeckh; Marissa B Wilck; Amelia A Langston; Al 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 237 KB

Vanganciclovir prophylaxis for the preve

Vanganciclovir prophylaxis for the prevention of cytomegalovirus reactivation and disease in allogeneic stem cell transplantation recipients

✍ M. Magalhaes-Silverman; T. Carter; R. Hohl; H. Shamsuddin; R. Gingrich 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 66 KB

A randomised, double-blinded, placebo-co

A randomised, double-blinded, placebo-controlled, pilot study of parenteral glutamine for allogeneic stem cell transplant patients

✍ N. M. A. Blijlevens; J. P. Donnelly; A. H. J. Naber; A. V. M. B. Schattenberg; B 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 112 KB

Randomized, placebo-controlled, double-b

Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation

✍ Michael Boeckh; Raleigh A. Bowden; Barry Storer; Nelson J. Chao; Ricardo Spielbe 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 957 KB

Efficacy and Safety of Maribavir Dosed a

Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled Trial

✍ D. J. Winston; F. Saliba; E. Blumberg; M. Abouljoud; J. B. Garcia-Diaz; J. A. Go 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 645 KB

CMX001 for Prevention and Control of CMV

CMX001 for Prevention and Control of CMV Infection in CMV-Seropositive Allogeneic Stem-Cell Transplant Recipients: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial of Safety, Tolerability and Antiviral Activity

✍ F.M. Marty; D. Winston; S.D. Rowley; M. Boeckh; E. Vance; G. Papanicolaou; A. Ro 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 100 KB